Advanced Infusion Therapy Company Eitan Medical Receives MDR Clearance For Flagship Sapphire Infusion System

March 9, 2021

Eitan Medical notes their Sapphire infusion system, the pump, accessories, and administration sets, have received EU Medical Device Regulation (MDR) 2017/45 certification. The approval was granted in January 2021.

“This is an important milestone for Eitan Medical, representing our commitment to meeting the most stringent regulatory requirements. We prioritized securing MDR clearance early this year, in order to meet the most stringent up to date standards continually enhancing quality for our customers.” said Judith Antler, Executive Vice President of Quality Assurance and Regulatory Affairs at Eitan Medical. “The sophisticated design of the Sapphire and its accessories enabled us to complete the processes required to meet MDR’s updated safety standards.”

Eitan Medical’s Sapphire™ infusion system serves clinicians in hospitals and home care environments across Europe. The Sapphire’s upgraded software Rev15, certified by EU MDR, delivers a simplified workflow, increasing its ease of use. Additionally, the upgraded Sapphire system offers a new fleet configuration management tool, newly developed administration sets, preset programs, and the FasTest PM preventative maintenance solution, designed for fast and efficient on-site fleet management.

“For over a decade, Eitan Medical has developed innovative, future-ready infusion solutions. Receiving MDR clearance was a critical priority for us to ensure that we continue to serve as a reliable partner to our Sapphire™ customers in hospitals, alternate site, homecare and pre-hospital settings,” said Chief Commercial Officer of Medication Delivery Solutions at Eitan Medical, Roger Massengale. “Achieving MDR clearance was not only necessary from a regulatory perspective, but demonstrates again, the safety of our products. Clinicians can rest assured that they are delivering optimal care to their patients with our infusion solutions.”

MDR is an expansion of European medical device regulations that emphasizes transparency, patient safety, and post-market surveillance. Following May 2021, medical devices, including infusion pumps, accessories, and administration sets, that are not MDR approved, can continue to be sold until 2024, after which they must be removed from the market. Other news here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version